Daiichi Sankyo Starts Phase III Japan Trials With Enbrel Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has begun Phase III trials in Japan with a biosimilar Enbrel (etanercept) for rheumatoid arthritis.